Information Provided By:
Fly News Breaks for March 21, 2018
CELG
Mar 21, 2018 | 05:14 EDT
JPMorgan analyst Cory Kasimov reinstated coverage with an Overweight rating and $110 price target. Before moving to a not rated designation the analyst had an Overweight rating on the shares. Kasimov continues to believe Celgene's valuation is "too compelling to ignore." He sees the company's "deep and broad pipeline" driving industry-leading growth through 2022.
News For CELG From the Last 2 Days
There are no results for your query CELG